INTRODUCTION
hematological malignancies, fungal infections, IFIs
HEMATOLOGICAL MALIGNANCIES, FUNGAL INFECTIONS
The incidence of invasive fungal infections (IFIs) has increased globally due to a substantial rise in the number of immunocompromised patients, including organ transplant recipients, individuals with hematological malignancies or on prolonged immunosuppressive therapy, the elderly, and premature infants (Fosmanogepix (FMGX, APX001/PF-07842805; formerly E1211) is the first member of the “gepix” class of antifungals and is a small-molecule intravenous (i.v.) and oral (p.o.) water-soluble phosphate prodrug under clinical development for the treatment of IFIs. FMGX is quickly and extensively metabolized by systemic alkaline phosphatases to the active moiety, manogepix (MGX, APX001A; formerly E1210) (MGX exhibits potent, broad-spectrum antifungal activity The efficacy of FMGX has been examined in several Development of FMGX has progressed to evaluations in a clinical phase 3 setting. Here, we present the pharmacokinetics (PK), safety, and tolerability of i.v. and p.o. FMGX formulations in healthy adult volunteers from the first two completed phase 1 clinical studies of FMGX.(The results of these studies were presented in part at IDWeek 2017, San Diego, CA [